Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of AD-214-02 vs Rabeprazole in Healthy Volunteers
NCT04622358Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-214-02 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma drug concentration-time curve at steady state at Day 29 and Change of integrated gastric acidity at Day 28. Started Dec 2020; status: completed.
02
Drugs
AD-214-02
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04622358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622358.